通气散方联合布地奈德鼓室注射治疗分泌性中耳炎临床观察  

Observation of Tongqi San Prescription Combined with Budesonide Intratympanic Injection in Treating SOM

作　　者：陈彤[1] 

机构地区：[1]甘肃省人民医院,甘肃兰州730000

出　　处：《新中医》2017年第2期121-123,共3页New Chinese Medicine

摘　　要：目的:观察通气散方联合布地奈德鼓室注射治疗分泌性中耳炎临床疗效。方法:将分泌性中耳炎患者90例按随机数字表法分为2组各45例。对照组采用布地奈德鼓室注射治疗,观察组联合通气散方治疗,比较2组临床疗效及药物安全性。结果:治疗后,2组不同频率下气导听力出现下降趋势,观察组治疗后0.5 k Hz、1 k Hz及2 k Hz下气导听力低于对照组(P<0.05)。观察组治疗后听力指标鼓室压及语频气导听阀指标改善优于对照组(P<0.05)。治疗后观察组不良反应发生率为4.44%,对照组为13.33%,2组比较,差异有统计学意义(P<0.05)。结论:在布地奈德鼓室注射治疗基础上联合通气散方治疗分泌性中耳炎疗效好且安全。Objective ： To observe clinical curative effect of Tongqi san prescription combined with Budesonide intratympanic injection in treating secretory otitis media（SOM）. Methods： Selected 90 patients with SOM and divided them into two groups of 45 cases in each. The control group was treated with budesonide intratympanic injection, and the observation group was given Tongqi san prescription combined with Budesonide intratympanic injection. Compared clinical curative effect and safety of drug in the two groups. Results： After treatment, air conduction hearing of the two groups appeared to decline in different frequency, and air conduction hearing of the observation group was lower than that of the control group in the frequency of 0. 5 k Hz, 1 k Hz and 2 k Hz（P 〈 0. 05）. The improvement of the hearing index tympanic pressure and speech frequency air conduction threshold audiometry of the observation group were better than those of the control group（P 〈 0.05）. After treatment,the incidencerate of adverse reaction was 4.44% and 13.33% in the observation group and the control group respectively,the difference being significant（P 〈 0.05）. Conclusion：Budesonide intratympanic injection combined with Tongqisan prescription has a good curative effect in treating SOM,which is safe.

关 键 词：分泌性中耳炎 通气散方 布地奈德 鼓室注射 不良反应 

分 类 号：R764.21[医药卫生—耳鼻咽喉科]